Form 10-K/A - Annual report [Section 13 and 15(d), not S-K Item 405]: [Amend]
SEC Accession No. 0000950170-25-058693
Filing Date
2025-04-25
Accepted
2025-04-25 16:05:10
Documents
16
Period of Report
2024-12-31

Document Format Files

Seq Description Document Type Size
1 10-K/A ikt-20241231.htm   iXBRL 10-K/A 911011
2 EX-31.1 ikt-ex31_1.htm EX-31.1 7993
3 EX-31.2 ikt-ex31_2.htm EX-31.2 8037
  Complete submission text file 0000950170-25-058693.txt   1639700

Data Files

Seq Description Document Type Size
4 XBRL TAXONOMY EXTENSION SCHEMA WITH EMBEDDED LINKBASES DOCUMENT ikt-20241231.xsd EX-101.SCH 93542
19 EXTRACTED XBRL INSTANCE DOCUMENT ikt-20241231_htm.xml XML 142068
Mailing Address 3350 RIVERWOOD PARKWAY SE, SUITE 1900 ATLANTA GA 30339
Business Address 3350 RIVERWOOD PARKWAY SE, SUITE 1900 ATLANTA GA 30339 678-392-3419
Inhibikase Therapeutics, Inc. (Filer) CIK: 0001750149 (see all company filings)

EIN.: 263407249 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 10-K/A | Act: 34 | File No.: 001-39676 | Film No.: 25873784
SIC: 2836 Biological Products, (No Diagnostic Substances)
(CF Office: 03 Life Sciences)